Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study
NCT ID: NCT00745043
Last Updated: 2024-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
11 participants
INTERVENTIONAL
2005-05-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Beta-blockade and Cardiopulmonary Exercise in COPD
NCT02380053
Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)
NCT00202176
What Influences Patient Outcome in Obstructive Airway Disease?
NCT01221480
An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI
NCT04717492
Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD
NCT01273298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R302
Daily placebo capsules
bronchodilator response
R303
Daily metoprolol 95mg capsules
bronchodilator response
R304
Daily propranolol 80mg capsules
bronchodilator response
Open Label
Daily Metoprolol 190mg capsules
bronchodilator response
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bronchodilator response
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \> 40 years of age
* \> 15 pack year smoking history
Exclusion Criteria
* Severe COPD FEV1 \< 30% or 1 L
* Not responsive the methacholine
40 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Waikato Hospital Research Fund
UNKNOWN
Waikato Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Respiratory Research Waikato Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bob Hancox, MD FRACP
Role: STUDY_DIRECTOR
Waikato Hospital Research Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Respiratory Medicine
Hamilton, Waikato Region, New Zealand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NTX/05/04/035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.